Selected Grants
COMBAT: A Phase I/IIa theranostic study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPR-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with ¿¿¿Lu-PSMA-617
Clinical TrialPrincipal Investigator · Awarded by Clarity Pharmaceuticals Pty Ltd (Clarity Pharmaceuticals) · 2024 - 2029BMS CA125-1008: AR degradation in mCRPC patients
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2024 - 2029PRESERVE-006: ONC-392 plus Pluvicto in ARTA resistant mCRPC
Clinical TrialPrincipal Investigator · Awarded by OncoC4 · 2024 - 2028Inhibiting Rev1-mediated DNA translesion synthesis for cancer therapy
ResearchCo Investigator · Awarded by National Cancer Institute · 2024 - 2028The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program
ResearchPreceptor · Awarded by National Cancer Institute · 2023 - 2028Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
ResearchCollaborator · Awarded by National Cancer Institute · 2022 - 2027SX-682 + Enzalutamide in Abiraterone-Resistant mCRPC
Clinical TrialPrincipal Investigator · Awarded by Syntrix Biosystems, Inc. · 2024 - 2027DoD: PCRP Clinical Consortium: Duke University Clinical Research Site
ResearchPrincipal Investigator · Awarded by Department of Defense · 2007 - 2026Defining clinically actionable subtypes of castration-resistant prostate cancer through epigenetic cell-free DNA analysis
ResearchCo Investigator · Awarded by Dana-Farber Cancer Institute · 2023 - 2026Blocking glutamine utilization in advanced and therapy-resistant prostate cancer
ResearchCo-Mentor · Awarded by Department of Defense · 2024 - 2026Validation of predictive liquid biomarkers for patients with metastatic prostate cancer
ResearchPrincipal Investigator · Awarded by University of Wisconsin - Madison · 2023 - 2026Validation of the CREB binding protein inhibitor, Pocenbrodib, as a novel therapy for advanced, hormone therapy-resistant prostate cancer
ResearchCo Investigator · Awarded by Pathos AI, Inc. · 2023 - 2026DAROL: Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients
ResearchPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2021 - 2026A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2021 - 2026A PHASE 1, MULTI-CENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CC-94676 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2021 - 2026Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2025Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC
ResearchCo-Principal Investigator · Awarded by National Cancer Institute · 2020 - 2025Targeting neuroendocrine cells in prostate cancer with small molecule and targeted radionuclide therapies
ResearchPrincipal Investigator · Awarded by Prostate Cancer Foundation · 2023 - 2025Protocol No. 20180146 entitled "A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2020 - 2025PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2025Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2025Study title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2019 - 2025A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2018 - 2025A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2020 - 2025Interrupting the aberrant cancer development sequence in epithelial cancer progression
ResearchMentor · Awarded by Prostate Cancer Foundation · 2021 - 2025A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2019 - 2024Targeting convergent mechanisms of castration resistant prostate cancer therapy resistance, metastasis, and immune evasion with AR-LDDs
ResearchCo Investigator · Awarded by Celgene Corporation · 2019 - 2024Exploiting Ferroptosis for the Treatment of RB1-Deficient Lethal Prostate Cancer
ResearchCo-Mentor · Awarded by Department of Defense · 2022 - 2024Evaluating the preclinical efficacy of multi-tyrosine kinase inhibitor TT-00420 in hormone therapy-resistant prostate cancer
ResearchConsultant · Awarded by TransThera Biosciences Co. Ltd · 2024 - 2024A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Biosplice Therapeutics, Inc · 2022 - 2024A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Biosplice Therapeutics, Inc · 2021 - 2024under protocol number 7051-ONC-101 entitled "A Phase 1 Study of FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer" (as it may be amended from time to time by Sponsor, the "Protocol"; the performance of the Protocol at all sites is
Clinical TrialPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2021 - 2024HOXB13 as a therapeutic target in prostate cancer
ResearchCo Investigator · Awarded by Prostate Cancer Foundation · 2020 - 2024ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Constellation Pharmaceuticals · 2019 - 2024VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177lu-Psma-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical TrialPrincipal Investigator · Awarded by Endocyte, Inc. · 2019 - 2024A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
Clinical TrialPrincipal Investigator · Awarded by Janssen Pharmaceutica, Inc. · 2018 - 2023Targeting Convergent Mechanisms of Therapy Resistance, Metastasis, and Immune Evasion with CBP inhibitors
ResearchCo Investigator · Awarded by FORMA Therapeutics, Inc. · 2020 - 2022PROPHECY CTC PSMA Project
ResearchCollaborator · Awarded by Epic Sciences, Inc · 2022 - 2022International Retrospective Collaborative Analysis of the Impact of Ablative Therapy Directed to the Local Tumor and/or Metastases for Patients with Oligometastatic Prostate Cancer¿
ResearchPrincipal Investigator · Awarded by Movember Foundation · 2021 - 2022Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis
ResearchCo Investigator · Awarded by Department of Defense · 2018 - 2022Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
ResearchPartnering PI · Awarded by Department of Defense · 2018 - 2022Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2018 - 2022NEPC Trial PD-1 Inhibition in Neuroendocrine-like Prostate Cancer (PD-1 Inhibition or Combination Checkpoint Immuntherapy of Neuroedocrine_Like Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2017 - 2022A Phase II Study of Navarixin (MK-7123) in Combination with Pembrolizumab (MK-3475) in Participants with Selected Advanced/Metastatic Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2018 - 2022A Randomized Phase 2 Study of Sipuleucel-T with or without Radium-223 in Men with Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2017 - 2021A Phase 1B, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have progressed followinIn
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2017 - 2021Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells
ResearchPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2016 - 2021A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate-Resistanct Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2020A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD) (Beigene)
Clinical TrialPrincipal Investigator · Awarded by BeiGene, Ltd · 2020 - 2020STREAM - Salvage Therapeutic Radiation with Enzalutamide and ADT in Men with Recurrent Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2014 - 2020Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)
ResearchPrincipal Investigator · Awarded by Prostate Cancer Foundation · 2014 - 2020A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2018 - 2020Pharmacology Industry Internships for Ph.D. Students
Inst. Training Prgm or CMEParticipating Faculty Member · Awarded by American Society for Pharmacology and Experimental Therapeutics · 2017 - 2019Pharmacodynamic Study of Radium-223 in Men with Bone Metastatic Castration-Resistant Prostate Cancer (CRPC)
Clinical TrialPrincipal Investigator · Awarded by Bayer Corporation · 2014 - 2019A Phase 2 Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Weill Medical College of Cornell University · 2013 - 2019Testing the efficacy of AR degrading compounds in enzalutamide-resistant prostate cancer
ResearchInvestigator · Awarded by Arvinas Inc. · 2017 - 2019AR variant regulation during EMT and disease progression
FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2018TAX 3503, A prospective registry -A Randomized, Open label, Muiticenter, Phase III, 2 Arm Study of Androgen Deprivation with Leuprilode +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following D. local therapy
Clinical TrialPrincipal Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2013 - 2017Developing and Validating Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2011 - 2016Alternative splicing and epithelial-mesenchymal plasticity in prostate tumors
ResearchCollaborating Investigator · Awarded by National Institutes of Health · 2008 - 2014External Relationships
- Arivan
- Astellas Pharma Inc.
- AstraZeneca
- Avoro
- Bayer
- Bristol-Myers Squibb
- COR2ED
- Cadence
- Clearview Health Partners
- Clinical Advances in Hematology Oncology
- Clinical Care Options
- Curium
- Exelixis, Inc.
- Expert Connect
- GLG
- Global Guidepoint
- GoodRx
- MCI India
- MJH Life Sciences
- Merck Sharpe & Dohme (Merck & Co, USA)
- Neil Love CME
- Pathos
- Pfizer Inc.
- Slingshot insights
- WebMD/Medscape
- Z Alpha
- eHealth China
- telix pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.